ICH Seeks To Resolve Impasse Over Q12 Legal Review This Week
Executive Summary
It remains uncertain whether a legal review by the European Commission that since June has delayed public consultation of draft ICH Q12 post-approval changes guideline can be resolved during this week's ICH meeting in Geneva.
You may also be interested in...
Global Post-Approval Changes Outlook Murky As Q12 Lurches Into Consultation
ICH finally proposes a way to resolve the regulatory complexity that has prevented drug makers from establishing and perfecting global approaches to manufacturing their drug products. But with legal concerns persisting in Europe and possibly lurking elsewhere, approval of ICH's draft Q12 guideline could be difficult.
Japan Commits to Comparability Protocols as ICH Q12 Takes Shape
Japan’s decision to adopt comparability protocols will help smooth the way for the global post-approval changes that Q12 will enable.
FDA Would Establish Conditions For Swift Manufacturing Changes
FDA draft 'conditions established' guidance proposes to smooth the way for continual improvement of manufacturing processes for drugs and biologics by saying which manufacturing changes don't need to be reported.